Automation Engineer (I, II, III) (South San Francisco)

Automation Engineer (I, II, III)

We are seeking an Automation Engineer to contribute to the development, implementation, and optimization of innovative lab automation systems. The role involves enabling scalable and robust end-to-end automated workflows for high-throughput cell therapy manufacturing QC testing.

The successful candidate will play a key role in developing and managing liquid handling methods, as well as supporting the integration of specified off-the-shelf instruments and custom hardware within a fully automated workcell. Collaborating closely with cross-functional teams, the hire will contribute to iterating on various aspects of system designs and developing strategies for workflow optimization. Additionally, the role involves leading the development and testing of specific verification and validation plans for our automation systems.

Candidates should enjoy working in a fast-paced, mission-driven environment and be prepared to tackle a broad selection of challenges as the company grows.

Responsibilities

• Transfer and validated manual to automated QC workflow steps
• Develop, validate, and optimize automated methods for sample preparation, analysis, and data collection
• Design and execute validation experiments to optimize assay and workflow parameters
• Conduct verification and validation testing of integrated systems to verify proper functionality and performance
• Analyze automation workflows to identify bottlenecks and areas for optimization
• Implement troubleshooting methodologies to identify and resolve complex assay method issues

Requirements

$90,000 - $210,000 a year

Cellares total compensation package contains competitive base salaries, highly subsidized Medical, Dental, and Vision Plans, 401(k) Matching, Free EV Charging, Onsite lunches, and Stock options. All displayed pay ranges are approximate, negotiable, and location dependent.

This is Cellares

Cellares is the first Integrated Development and Manufacturing Organization (IDMO) and takes an Industry 4.0 approach to mass manufacturing the living drugs of the 21st century. The company is both developing and operating integrated technologies for cell therapy manufacturing to accelerate access to life-saving cell therapies. The company's Cell Shuttle integrates all the technologies required for the entire manufacturing process in a flexible and high-throughput platform that delivers true walk-away, end-to-end automation. Cell Shuttles will be deployed in Cellares' Smart Factories around the world to meet total patient demand for cell therapies at global scale. Partnering with Cellares enables academics, biotechs, and pharma companies to accelerate drug development and scale out manufacturing, lower process failure rates, lower manufacturing costs, and meet global patient demand.

The company is headquartered in South San Francisco, California with its commercial-scale IDMO Smart Factory in Bridgewater, New Jersey. The company is backed by world-class investors and has raised over $355 million in financing.